肾康注射液联合厄贝沙坦治疗早期糖尿病肾病的疗效观察

Observation on the Efficacy of Shenkang Injection Combined with Irbesartan in the Treatment of Early Diabetic Nephropathy

目的 探讨肾康注射液联合厄贝沙坦治疗早期糖尿病肾病的疗效。方法 选取2019年1月至2020年12月我院收治的88例糖尿病肾病患者,随机分为对照组和观察组各44例。对照组采用厄贝沙坦治疗,观察组采用肾康注射液联合厄贝沙坦治疗。比较两组的血液流变学指标、血脂指标、 BUN、 Cr、 UAER。结果 治疗后,观察组的红细胞压积、纤维蛋白原、血浆高黏度、全血低切黏度、全血高切黏度均低于对照组(P<0.05);观察组的LDL-C、 TG、 TC水平低于对照组,HDL-C水平高于对照组(P<0.05);观察组的BUN、 Cr、 UAER均低于对照组(P<0.05)。结论 肾康注射液联合厄贝沙坦治疗早期糖尿病肾病患者疗效确切,能够显著改善患者的血液流变性,降低血脂水平与UAER,值得临床推广。

Objective To explore the efficacy of Shenkang injection combined with irbesartan in the treatment of early diabetic nephropathy.Methods 88 patients with diabetic nephropathy admitted to our hospital from January 2019 to December 2020 were selected and randomly divided into control group and observation group,with 44 cases in each group.The control group was treated with irbesartan,and the observation group was treated with Shenkang injection combined with irbesartan.The hemorheological indicators,blood lipid indicators,BUN,Cr and UAER were compared between the two groups.Results After treatment,the hematocrit,fibrinogen,plasma high viscosity,whole blood low shear viscosity and whole blood high shear viscosity of the observation group were lower than those of the control group(P<0.05);The LDL-C,TG and TC levels of the observation group were lower than those of the control group,while the HDL-C level was higher than that of the control group(P<0.05);The BUN,Cr and UAER of the observation group were lower than those of the control group(P<0.05).Conclusions Shenkang injection combined with irbesartan in the treatment of patients with early diabetic nephropathy has certain efficacy,which can improve the hemorheology,and reduce the blood lipid level and UAER,which is worthy of clinical promotion.